
Oculis Holding AG
NASDAQ:OCS
18.02 (USD) • At close April 16, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Oculis Holding AG |
Symbool | OCS |
Munteenheid | USD |
Prijs | 18.02 |
Beurswaarde | 864,960,000 |
Dividendpercentage | 0% |
52-weken bereik | 10.79 - 23.08 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Riad Sherif M.B.A., M.D. |
Website | https://oculis.com |
An error occurred while fetching data.
Over Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)